Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$5.2MCash on Hand
8mo Cash Runway
Follow RDHL by emailGet an email when RDHL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RDHL, unsubscribe in one click. Privacy
📣 What RDHL Says Is Next
this year · “We have designed a Phase 2 Proof-of-Concept study of RHB-102 for GLP-1/GIP receptor agonist therapy-associated GI side effects, planned to commence as early as possible this year.”
Company press release, Jan 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 2, 2026 ·
Clinical trial RedHill reported in vitro studies from two microbiology centers confirming RHB-204 kills Mycobacterium avium subspecies paratuberculosis (MAP) and is comparable to RHB-104 in long-term intracellular culture, spot and phage assays. Lower doses of two active ingredients were needed versus RHB-104. Form 6-K · SEC filing · Press release
Oct 21, 2026 ·
Deal RedHill regained ex-North America rights to RHB-102 after the License Agreement with Hyloris was terminated effective October 15, 2026. Hyloris agreed to pay a one-time break-up fee of $200,000. Form 6-K · SEC filing
Oct 19, 2026 ·
The University of Oklahoma received a $2.9 million five-year NCI grant to fund clinical trials of RedHill's opaganib given after CAR T-cell therapy in ultra-high-risk multiple myeloma. The Phase 1b trial plans to enroll up to 18 patients and the Phase 2 up to 21. Form 6-K · SEC filing · Press release
Oct 7, 2026 ·
Listing Nasdaq granted RedHill Biopharma an additional 180 calendar days, until April 5, 2027, to regain compliance with the $1.00 minimum bid price rule. The ADSs continue trading on The Nasdaq Capital Market under RDHL. Form 6-K · SEC filing
Sep 30, 2026 ·
Deal Reported first half 2026 results and operational highlights. Paid $12 million upfront to Ferring for U.S. and global commercialization rights to Rebyota and Clenpiq, funded by $18 million received from the Talicia divestment. Rebyota and Clenpiq generated approximately $37.5 million in 2025 net sales under Ferring. Form 6-K · SEC filing · Press release
Sep 30, 2026 ·
Deal Redhill sold its 70% stake in Talicia Holdings to an Apotex unit for $18.0M upfront plus up to $35.0M in milestones. It also signed a Ferring deal for global Rebyota rights and U.S. Clenpiq rights with a $12M upfront payment. Stockholders' equity is believed to exceed $5M. Form 6-K · SEC filing
Sep 1, 2026 ·
Deal RedHill Biopharma acquired exclusive global commercialization rights to Rebyota and exclusive U.S. rights to Clenpiq from Ferring for a $12 million upfront payment, plus tiered royalties of 5% to 20% and potential milestones. Rebyota and Clenpiq had 2025 net sales of about $16.9 million and $20.6 million. Form 6-K · SEC filing · Press release
Aug 31, 2026 ·
Deal Divested its 70% interest in Talicia Holdings to a subsidiary of Apotex Health Corp. for an $18 million upfront cash payment plus up to $35 million in potential worldwide net sales milestones. Agreed to a five-year non-compete for the product in the U.S., and a six-month transition services agreement. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2022 · Phase 2 · Results Expected · A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma Registry primary completion date, not a results date
Jul 2021 · Phase 2/3 · Results Expected · Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia Registry primary completion date, not a results date
Nov 2020 · Phase 2 · Results Expected · A Study of Opaganib in Coronavirus Disease 2019 Pneumonia Registry primary completion date, not a results date
Nov 2018 · Phase 3 · Results Expected · Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease Registry primary completion date, not a results date
Oct 2018 · Phase 3 · Results Expected · ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator Registry primary completion date, not a results date
May 2018 · Phase 3 · Results Expected · Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not RDHL's own candidates): Amoxicillin, Hydroxychloroquine Sulfate.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
RDHL holds $5.2M in cash and short-term investments and burns about $1.9M/quarter from operations,
an estimated runway of 8 months at that rate (BioRadar estimate, not company guidance).
Share count 50,923,261,000 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full RDHL picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RDHL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.